Format

Send to

Choose Destination
Acta Haematol. 2011;125(3):145-52. doi: 10.1159/000322248. Epub 2010 Dec 24.

Clinical follow-up of hydroxyurea-treated adults with sickle cell disease.

Author information

1
Sickle Cell Disease Center, Groupe Hospitalier Albert-Chenevier - Henri-Mondor, AP-HP, Créteil, France. ruben.nzouakou@hmn.aphp.fr

Abstract

Hydroxyurea-derived clinical and biological benefits and safety were retrospectively studied for 123 adult patients from 2 sickle cell disease referral centers during a total follow-up of 654 patient-years and total hydroxyurea exposure of 549 patient-years. Fifty-six adverse events occurred (incidence: 12%/patient-year), with leg ulcers being the most frequent. Adverse events could arise at any time and were usually reversible. No malignancy was observed. Clinical and biological benefits of our cohort were similar to those previously reported. Based on this relatively long retrospective study, the risk/benefit ratio for moderate hydroxyurea doses was satisfactory.

PMID:
21196716
DOI:
10.1159/000322248
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for S. Karger AG, Basel, Switzerland
Loading ...
Support Center